Iron Chelation Therapy In The Management Of Transfusion-related Cardiac Iron Overload

Iron overload is one of the major causes of morbidity and death in patients undergoing chronic transfusion therapy. Furthermore, excessive iron accumulation in the heart may result in impaired left ventricular dysfunction. With accurate monitoring techniques and treatment regimens, progression of heart complications can be followed, and their natural history changed. Iron chelation therapy is the mainstay of prevention and reversal of myocardial iron overload. Despite recent appraisals of general chelating strategies, the management of iron chelation in chronically transfused patients with a focus on the heart has not been extensively assessed. New studies published in the past couple of years have provided important new data in this topic and therefore this review summarizes the major studies that examined the removal of iron from the heart with the iron chelators: deferoxamine, deferiprone, and deferasirox. Since chronically transfused patients and their cardiac clinical presentations vary widely, this review tries to identify-with each drug-the precise scenarios evaluated, linking patients' baseline characteristics, clinical setting, and drug intake and dosing. Ultimately, by stratifying patients according to their cardiac iron overload status and ventricular function, this review identifies possible approaches for the initial treatment and follow-up of transfusion-related cardiac iron overload. © 2012 American Association of Blood Banks.521022562268Telfer, P., Update on survival in thalassemia major (2009) Hemoglobin, 33 (1 SUPPL.), pp. S76-S80Taher, A.T., Musallam, K.M., Inati, A., Iron overload: Consequences, assessment, and monitoring (2009) Hemoglobin, 33 (1 SUPPL.), pp. S46-S57Gujja, P., Rosing, D.R., Tripodi, D.J., Shizukuda, Y., Iron overload cardiomyopathy: Better understanding of an increasing disorder (2010) J Am Coll Cardiol, 56, pp. 1001-1012Fernandes, J.L., Fabron Jr., A., Verissimo, M., Early cardiac iron overload in children with transfusion-dependent anemias (2009) Haematologica, 94, pp. 1776-1777Anderson, L.J., Holden, S., Davis, B., Prescott, E., Charrier, C.C., Bunce, N.H., Firmin, D.N., Pennell, D.J., Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload (2001) Eur Heart J, 22, pp. 2171-2179Carpenter, J.P., He, T., Kirk, P., Roughton, M., Anderson, L.J., De Noronha, S.V., Sheppard, M.N., Pennell, D.J., On T2* magnetic resonance and cardiac iron (2011) Circulation, 123, pp. 1519-1528Liu, P., Olivieri, N., Iron overload cardiomyopathies: New insights into an old disease (1994) Cardiovasc Drugs Ther, 8, pp. 101-110Chouliaras, G., Berdoukas, V., Ladis, V., Kattamis, A., Chatziliami, A., Fragodimitri, C., Karabatsos, F., Karagiorga-Lagana, M., Impact of magnetic resonance imaging on cardiac mortality in thalassemia major (2011) J Magn Reson Imaging, 34, pp. 56-59Modell, B., Khan, M., Darlison, M., Westwood, M.A., Ingram, D., Pennell, D.J., Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance (2008) J Cardiovasc Magn Reson, 10, p. 42Kremastinos, D.T., Farmakis, D., Aessopos, A., Hahalis, G., Hamodraka, E., Tsiapras, D., Keren, A., Beta-thalassemia cardiomyopathy: History, present considerations, and future perspectives (2010) Circ Heart Fail, 3, pp. 451-458Modell, B., Darlison, M., Global epidemiology of haemoglobin disorders and derived service indicators (2008) Bull World Health Organ, 86, pp. 480-487Porter, J.B., Optimizing iron chelation strategies in beta-thalassaemia major (2009) Blood Rev, 23 (1 SUPPL.), pp. S3-S7Brittenham, G.M., Iron-chelating therapy for transfusional iron overload (2011) N Engl J Med, 364, pp. 146-156Cappellini, M.D., Musallam, K.M., Taher, A.T., Overview of iron chelation therapy with desferrioxamine and deferiprone (2009) Hemoglobin, 33 (1 SUPPL.), pp. S58-S69Propper, R.D., Cooper, B., Rufo, R.R., Nienhuis, A.W., Anderson, W.F., Bunn, H.F., Rosenthal, A., Nathan, D.G., Continuous subcutaneous administration of deferoxamine in patients with iron overload (1977) N Engl J Med, 297, pp. 418-423Marcus, R.E., Davies, S.C., Bantock, H.M., Underwood, S.R., Walton, S., Huehns, E.R., Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major (1984) Lancet, 1, pp. 392-393Flynn, D.M., Hoffbrand, A.V., Politis, D., Subcutaneous desferrioxamine: The effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography (1982) Birth Defects Orig Artic ser, 18, pp. 347-353Freeman, A.P., Giles, R.W., Berdoukas, V.A., Walsh, W.F., Choy, D., Murray, P.C., Early left ventricular dysfunction and chelation therapy in thalassemia major (1983) Ann Intern Med, 99, pp. 450-454Brittenham, G.M., Griffith, P.M., Nienhuis, A.W., McLaren, C.E., Young, N.S., Tucker, E.E., Allen, C.J., Harris, J.W., Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major (1994) N Engl J Med, 331, pp. 567-573Kremastinos, D.T., Tsetsos, G.A., Tsiapras, D.P., Karavolias, G.K., Ladis, V.A., Kattamis, C.A., Heart failure in beta thalassemia: A 5-year follow-up study (2001) Am J Med, 111, pp. 349-354Aessopos, A., Farmakis, D., Deftereos, S., Tsironi, M., Tassiopoulos, S., Moyssakis, I., Karagiorga, M., Thalassemia heart disease: A comparative evaluation of thalassemia major and thalassemia intermedia (2005) Chest, 127, pp. 1523-1530Gabutti, V., Piga, A., Results of long-term iron-chelating therapy (1996) Acta Haematol, 95, pp. 26-36Olivieri, N.F., Nathan, D.G., MacMillan, J.H., Wayne, A.S., Liu, P.P., McGee, A., Martin, M., Cohen, A.R., Survival in medically treated patients with homozygous beta-thalassemia (1994) N Engl J Med, 331, pp. 574-578Olivieri, N.F., Brittenham, G.M., Iron-chelating therapy and the treatment of thalassemia (1997) Blood, 89, pp. 739-761Olivieri, N.F., Sher, G.D., MacKinnon, J.A., The first prospective randomized trial of subcutaneous deferoxamine and the orally active iron chelating agent L1 (1994) Blood, 84 (1), pp. 363a. , (Suppl):[abst 1436]Kontoghiorghes, G.J., Aldouri, M.A., Hoffbrand, A.V., Barr, J., Wonke, B., Kourouclaris, T., Sheppard, L., Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one (1987) Br Med J (Clin Res Ed), 295, pp. 1509-1512Galia, M., Midiri, M., Bartolotta, V., Morabito, A., Rizzo, M., Mangiagli, A., Malizia, R., Maggio, A., Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with deferoxamine or deferiprone during a randomized multicenter prospective clinical study (2003) Hemoglobin, 27, pp. 63-76Olivieri, N.F., Koren, G., Hermann, C., Bentur, Y., Chung, D., Klein, J., St Louis, P., Templeton, D.M., Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients (1990) Lancet, 336, pp. 1275-1279Hoyes, K.P., Porter, J.B., Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools (1993) Br J Haematol, 85, pp. 393-400Anderson, L.J., Wonke, B., Prescott, E., Holden, S., Walker, J.M., Pennell, D.J., Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia (2002) Lancet, 360, pp. 516-520Maggio, A., D'Amico, G., Morabito, A., Capra, M., Ciaccio, C., Cianciulli, P., Di Gregorio, F., Midiri, M., Deferiprone versus deferoxamine in patients with thalassemia major: A randomized clinical trial (2002) Blood Cells Mol Dis, 28, pp. 196-208Piga, A., Gaglioti, C., Fogliacco, E., Tricta, F., Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: A retrospective analysis (2003) Haematologica, 88, pp. 489-496Borgna-Pignatti, C., Cappellini, M.D., De Stefano, P., Del Vecchio, G.C., Forni, G.L., Gamberini, M.R., Ghilardi, R., Cnaan, A., Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major (2006) Blood, 107, pp. 3733-3737Pennell, D.J., Berdoukas, V., Karagiorga, M., Ladis, V., Piga, A., Aessopos, A., Gotsis, E.D., Galanello, R., Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis (2006) Blood, 107, pp. 3738-3744Maggio, A., Vitrano, A., Capra, M., Cuccia, L., Gagliardotto, F., Filosa, A., Magnano, C., Rigano, P., Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies (2009) Blood Cells Mol Dis, 42, pp. 247-251Berdoukas, V., Chouliaras, G., Moraitis, P., Zannikos, K., Berdoussi, E., Ladis, V., The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: A clinical observational study (2009) J Cardiovasc Magn Reson, 11, p. 20Pepe, A., Meloni, A., Capra, M., Cianciulli, P., Prossomariti, L., Malaventura, C., Putti, M.C., Maggio, A., Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: Cardiac iron and function comparison determined by quantitative magnetic resonance imaging (2011) Haematologica, 96, pp. 41-47(2011) FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body, , http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm275814.htm, US Food and Drug Administration. [cited 2011 Feb 15](2009) Ferriprox (Deferiprone): Summary of Product Characteristics, , European Medicines AgencyCeci, A., Baiardi, P., Felisi, M., Cappellini, M.D., Carnelli, V., De Sanctis, V., Galanello, R., Tricta, F., The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients (2002) Br J Haematol, 118, pp. 330-336Wonke, B., Wright, C., Hoffbrand, A.V., Combined therapy with deferiprone and desferrioxamine (1998) Br J Haematol, 103, pp. 361-364Link, G., Konijn, A.M., Breuer, W., Cabantchik, Z.I., Hershko, C., Exploring the "iron shuttle" hypothesis in chelation therapy: Effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture (2001) J Lab Clin Med, 138, pp. 130-138Kolnagou, A., Kontoghiorghes, G.J., Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators (2006) Hemoglobin, 30, pp. 239-249Daar, S., Pathare, A.V., Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload (2006) Ann Hematol, 85, pp. 315-319Christoforidis, A., Haritandi, A., Tsatra, I., Tsitourides, I., Karyda, S., Athanassiou-Metaxa, M., Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: Comparison between different chelation regimens (2007) Eur J Haematol, 78, pp. 52-57Tanner, M.A., Galanello, R., Dessi, C., Smith, G.C., Westwood, M.A., Agus, A., Roughton, M., Pennell, D.J., A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance (2007) Circulation, 115, pp. 1876-1884Tanner, M.A., Galanello, R., Dessi, C., Smith, G.C., Westwood, M.A., Agus, A., Pibiri, M., Pennell, D.J., Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction (2008) J Cardiovasc Magn Reson, 10, p. 12Mamtani, M., Kulkarni, H., Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: A systematic review and meta-analysis (2008) Br J Haematol, 141, pp. 882-890Porter, J.B., Deferasirox: An update (2009) Hemoglobin, 33 (1 SUPPL.), pp. S70-S75Galanello, R., Piga, A., Alberti, D., Rouan, M.C., Bigler, H., Sechaud, R., Safety, tolerability, and pharmacokinetics of icl670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia (2003) J Clin Pharmacol, 43, pp. 565-572(2011) Exjade 125 mg, 250 mg, 500 mg Dispersible Tablets-summary of Product Characteristics, , http://www.medicines.org.uk/emc/medicine/18805/SPC/, Novartis Pharmaceuticals UK Ltd. Electronic Medicines Compendium (eMC). [cited 2012 Feb 15]Glickstein, H., El, R.B., Shvartsman, M., Cabantchik, Z.I., Intracellular labile iron pools as direct targets of iron chelators: A fluorescence study of chelator action in living cells (2005) Blood, 106, pp. 3242-3250Glickstein, H., El, R.B., Link, G., Breuer, W., Konijn, A.M., Hershko, C., Nick, H., Cabantchik, Z.I., Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences (2006) Blood, 108, pp. 3195-3203Gattermann, N., Finelli, C., Porta, M.D., Fenaux, P., Ganser, A., Guerci-Bresler, A., Schmid, M., Rose, C., Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year epic study (2010) Leuk Res, 34, pp. 1143-1150Lee, J.W., Yoon, S.S., Shen, Z.X., Ganser, A., Hsu, H.C., Habr, D., Domokos, G., Porter, J.B., Iron chelation therapy with deferasirox in patients with aplastic anemia: A subgroup analysis of 116 patients from the epic trial (2010) Blood, 116, pp. 2448-2454Porter, J.B., Lin, K.H., Beris, P., Forni, G.L., Taher, A., Habr, D., Domokos, G., Thein, S.L., Response of iron overload to deferasirox in rare transfusion-dependent anaemias: Equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias (2011) Eur J Haematol, 87, pp. 338-348. , EPIC study investigatorsPennell, D.J., Porter, J.B., Cappellini, M.D., El-Beshlawy, A., Chan, L.L., Aydinok, Y., Elalfy, M.S., Taher, A., Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia (2010) Blood, 115, pp. 2364-2371Pennell, D., Carpenter, J., Roughton, M., Cabantchik, Z., On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure (2011) J Cardiovasc Magn Reson, 13, p. 45Pennell, D., Porter, J.B., Cappellini, M.D., Chan, L.L., El-Beshlawy, A., Aydinok, Y., Ibrahim, H., Taher, A., Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major (2012) Haematologica, 97. , [Epub ahead of print]Wood, J.C., Kang, B.P., Thompson, A., Giardina, P., Harmatz, P., Glynos, T., Paley, C., Coates, T.D., The effect of deferasirox on cardiac iron in thalassemia major: Impact of total body iron stores (2010) Blood, 116, pp. 537-543Wood, J.C., Glynos, T., Thompson, A., Giardina, P., Harmatz, P., Kang, B.P., Paley, C., Coates, T.D., Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial (2010) Am J Hematol, 85, pp. 818-819Pathare, A., Taher, A., Daar, S., Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major (2010) Ann Hematol, 89, pp. 405-409Kontoghiorghes, G.J., Introduction of higher doses of deferasirox: Better efficacy but not effective iron removal from the heart and increased risks of serious toxicities (2010) Expert Opin Drug Saf, 9, pp. 633-641Taher, A., Cappellini, M.D., Vichinsky, E., Galanello, R., Piga, A., Lawniczek, T., Clark, J., Porter, J.B., Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload (2009) Br J Haematol, 147, pp. 752-759Cappellini, M.D., Porter, J., El-Beshlawy, A., Li, C.K., Seymour, J.F., Elalfy, M., Gattermann, N., Kattamis, A., Tailoring iron chelation by iron intake and serum ferritin: The prospective epic study of deferasirox in 1744 patients with transfusion- dependent anemias (2010) Haematologica, 95, pp. 557-566Davis, B.A., Porter, J.B., Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia (2000) Blood, 95, pp. 1229-1236Anderson, L.J., Westwood, M.A., Holden, S., Davis, B., Prescott, E., Wonke, B., Porter, J.B., Pennell, D.J., Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: A prospective study using T2* cardiovascular magnetic resonance (2004) Br J Haematol, 127, pp. 348-355Mant, J., Al-Mohammad, A., Swain, S., Laramee, P., Management of chronic heart failure in adults: Synopsis of the National Institute for Health and Clinical Excellence guideline (2011) Ann Intern Med, 155, pp. 252-259Aessopos, A., Farmakis, D., Andreopoulos, A., Tsironi, M., Assessment and treatment of cardiac iron overload in thalassemia (2009) Hemoglobin, 33 (1 SUPPL.), pp. S87-S92Viprakasit, V., Lee-Lee, C., Chong, Q.T., Lin, K.H., Khuhapinant, A., Iron chelation therapy in the management of thalassemia: The Asian perspectives (2009) Int J Hematol, 90, pp. 435-445Angelucci, E., Barosi, G., Camaschella, C., Cappellini, M.D., Cazzola, M., Galanello, R., Marchetti, M., Tura, S., Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders (2008) Haematologica, 93, pp. 741-752Cappellini, M.D., Cohen, A., Eleftheriou, A., Piga, A., Porter, J., Taher, A., Iron overload (2008) Guidelines for the Clinical Management of Thalassemia, pp. 33-63. , Eleftheriou A. editor. Nicosia, Cyprus: Thalassemia International Federation;. pCogliandro, T., Derchi, G., Mancuso, L., Mayer, M.C., Pannone, B., Pepe, A., Pili, M., Maggio, A., Guideline recommendations for heart complications in thalassemia major (2008) J Cardiovasc Med (Hagerstown), 9, pp. 515-525Kremastinos, D.T., Farmakis, D., Iron overload cardiomyopathy in clinical practice (2011) Circulation, 124, pp. 2253-2263Kirk, P., Roughton, M., Porter, J.B., Walker, J.M., Tanner, M.A., Patel, J., Wu, D., Pennell, D.J., Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major (2009) Circulation, 120, pp. 1961-1968Donabedian, A., The quality of care. How can it be assessed? (1988) JAMA, 260, pp. 1743-1748Abergel, R.J., Raymond, K.N., Multidentate terephthalamidate and hydroxypyridonate ligands: Towards new orally active chelators (2011) Hemoglobin, 35, pp. 276-290Carpenter, J.P., Taigang, H., Kirk, P., Anderson, L.J., Porter, J., Fernandes, J.L., Pennell, D., Worldwide survy of T2* cardiovascular magnetic resonance in thalassaemia (2011) J Cardiovasc Magn Reson, 13 (1 SUPPL.), pp. O15Oudit, G.Y., Sun, H., Trivieri, M.G., Koch, S.E., Dawood, F., Ackerley, C., Yazdanpanah, M., Backx, P.H., L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy (2003) Nat Med, 9, pp. 1187-1194Pennell, D.J., Porter, J.B., Cappellini, M.D., Chan, L.L., El-Beshlawy, A., Aydinok, Y., Ibrahim, H., Taher, A., Continued improvement in myocardial T2* over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload (2011) Haematologica, 96, pp. 48-5